Molecular Imaging with 11C-PD153035 PET/CT for Predicting and Monitoring Responsiveness of Non-small Cell Lung Cancer to EGFR-TKI

被引：0
|
作者：
Meng, X. [1 ]
Sun, X. D. [1 ]
Ma, L. [1 ]
Kong, L. [1 ]
Zhao, S. Q. [1 ]
Yang, G. R. [1 ]
Zhang, P. L. [1 ]
Yu, J. M. [1 ]
机构：
[1] Shandong Canc Hosp, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2010.07.404
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S164 / S164
页数：1
相关论文
共 50 条
  • [21] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [22] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [23] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, 11 (04) : 270 - 276
  • [24] The pilot study of relationship between 11C-PD153035 PET/CT imaging and radiotherapy on advanced NSCLC
    Yang, Guoren
    Zhao, Fen
    Zhao, Shuqiang
    Yu, Jinming
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [25] Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
    Tanzawa, Shigeru
    Ishihara, Masashi
    Haruyama, Terunobu
    Ochiai, Ryosuke
    Sakamoto, Takahiko
    Honda, Takeshi
    Ota, Shuji
    Ichikawa, Yasuko
    Watanabe, Kiyotaka
    Seki, Nobuhiko
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (06) : 2223 - 2229
  • [26] Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer
    Ko, J.
    Kim, Y.
    Park, M.
    Cui, Z.
    Ahn, M.
    Park, K.
    EJC SUPPLEMENTS, 2008, 6 (09): : 29 - 30
  • [27] Is early 18F-FDG PET useful for predicting pathologic response to EGFR-TKI in resectable non-small cell lung cancer?
    Van Gool, M. H.
    Aukema, T. S.
    Schaake, E. E.
    Olmos, R. A. Valdes
    Teertstra, J.
    Van Pel, R.
    Burgers, J. A.
    Van Tinteren, H.
    Klomp, Elm.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S811 - S812
  • [28] Continuing EGFR-TKI in Combination with Regional Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR(+) Non-Small Cell Lung Cancer
    Zhang, Jie
    Qi, Huiwei
    Wang, Sen
    Ni, Juan H.
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S524 - S524
  • [29] The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer
    Cheng, Zhinan
    Cui, Hongwei
    Wang, Yaqi
    Yang, Jin
    Lin, Chunyang
    Shi, Xiaoyu
    Zou, Yuxiu
    Chen, Jing
    Jia, Xiaoqiong
    Su, Liqing
    ONCOLOGY REPORTS, 2024, 51 (01)
  • [30] Effect of EGFR-TKI targeted therapy in patients with advanced non-small cell lung cancer
    Yan, Meihao
    Chen, Shanshan
    Fan, Hongtao
    Hong, Yuancheng
    Huang, Wencheng
    Lin, Zhimin
    Lai, Zhangchao
    Hong, Liyue
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (11): : 7916 - 7923
12345